Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Nektar Therapeutics | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Nektar Therapeutics

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Nektar Therapeutics

2Q Revenues: $60 million (+110%)

2Q Loss: $63 million (loss of $27 million in 2Q2005)

YTD Revenues: $89 million (+56%)

YTD Loss: $96 million (loss of $53 million YTD2005)

Comments: In the quarter, product sales and royalty revenue was $44 million, including three months of Exubera product sales to Pfizer, compared to $5.5 million in 2Q2005. The company’s lead product, Amphotericin B Inhalation Powder, received Orphan Drug and Fast Track designation, while its PEGylated pain-related therapy completed a proof-of-concept trial in humans. Also in the quarter, the company closed its Bradford UK site as part of its strategic focus.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters